Gilenya Side Effects Being Reviewed by European, U.S. Regulators

Staff Writers

Add Your Comments

European regulators have placed Gilenya, Novartis’s multiple-sclerosis drug, under review due to potential links to heart problems.

The European Medicines Agency (EMA) announced on Friday that it has begun a review of Gilenya side effects and benefits after reports that a patient in the U.S. died of heart problems less than 24 hours after taking the drug.

Other patients have reported heart problems from Gilenya as well, and concerns have already sparked a Gilenya investigation in the United States by the FDA.

Do You Know about…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION
Spinal-Cord-Stimulation-Lawsuit
Spinal-Cord-Stimulation-Lawsuit

Do You Know About…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION

Gilenya (fingolimod) is a Novartis drug approved in 2010 as an oral treatment for relapsing forms of MS in adults. It is used to reduce how often flare-ups occur and to delay the onset of physical disability caused by MS.

While the EMA conducts its review, it’s Committee for Medicinal Products for Human Use (CHMP) has told doctors to more closely monitor patients after giving them their first dose of Gilenya. CHMP recommends that doctors conduct electrocardiogram (ECG) monitoring before treatment and continue monitoring for the six hours after the patient takes the first dose.

The risk of some heart irregularities after the first dose were a concern before the drug was approved. Known side effects of Gilenya include a decrease in heart rate and/or atrioventricular conduction after the first dose. It is also known to increase the risks of developing heart blocks or bradycardia when taken with some other drugs, including beta blockers and calcium channel blockers.

In the United States, the FDA is recommending that patients be informed Gilenya may cause serious side effects, such as a low heart rate, that can cause symptoms including dizziness, fatigue and palpitations after the first dose. The heart rate typically returns to normal within the first month of taking the drug. Patients should contact their health care provider if these symptoms occur.

The CHMP anticipates that the review into the potential Gilenya side effects will be complete by March.

Tags: Gilenya, Heart Failure, Multiple Sclerosis, Novartis

More Lawsuit Stories

1 Comments

Lorraine
I suffered a gilenya side effect in December, 2011. I suffered from PRES posterior reversible encephalopathy syndrome. I had high BP and seizures.

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Depo-Provera Meningioma Warning Update Should Be Added to Birth Control Shot Lawsuit
A Depo-Provera meningioma lawsuit argues that Pfizer had a duty to warn women about scientific evidence linking the birth control shot to potential brain tumor growth yet failed to do so.
Judges Will Consider MDL for Dupixent Cancer Lawsuits Late Next Month
A group of federal judges will determine whether all Dupixent cancer lawsuits should be formed into a multidistrict litigation, following oral arguments set for May 28.
MORE ABOUT: DUPIXENT LAWSUIT
SCS Injury Lawsuit Alleges Unlicensed Abbott Representatives Modified Device After Implantation
A product liability lawsuit alleges unlicensed Abbott representatives made real-time spinal cord stimulator programming decisions based on a Texas woman’s responses, improperly modifying the device and contributing to her injuries.